Stockscreener 앱 받기
0.0005
28.57%
-0.0002
전일 마감가:
$0.0007
열려 있는:
$0.0005
하루 거래량:
1,998
Relative Volume:
49.06
시가총액:
$N/A
수익:
-
순이익/손실:
$-13.49M
주가수익비율:
-0.00028
EPS:
-1.7861
순현금흐름:
$-7.62M
1주 성능:
-28.57%
1개월 성능:
-28.57%
6개월 성능:
-93.93%
1년 성능:
-85.81%
1일 변동 폭
$0.0005
$0.0005
1주일 범위
$0.0005
$0.0005
52주 변동 폭
$0.0005
$0.0007
팩스메디카 Stock (PXMD) Company Profile
Compare PXMD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PXMD
Paxmedica Inc
|
0.0005 | 0 | 0 | -13.49M | -7.62M | -1.7861 |
VRTX
Vertex Pharmaceuticals Inc
|
479.92 | 118.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
626.65 | 64.79B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.48 | 53.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.56 | 38.48B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
168.09 | 36.04B | 742.00K | -1.37B | -1.07B | -7.0731 |
팩스메디카 주식(PXMD)의 최신 뉴스
PaxMedica, Inc. has filed an IPO in the amount of $18.4575 million. - marketscreener.com
Strategic Execution in Focus for Paxmedica Investors - AD HOC NEWS
ProMetic Life Sciences (OTCMKTS:PFSCF) & PaxMedica (NASDAQ:PXMD) Financial Contrast - Defense World
Comparing PaxMedica (NASDAQ:PXMD) & ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Paxmedica’s PAX-101 Under the Microscope: Pipeline Progress and FDA Milestones - AD HOC NEWS
MorphoSys (NASDAQ:MOR) vs. PaxMedica (NASDAQ:PXMD) Head to Head Comparison - Defense World
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
QBIO Stock Price, News & Analysis - Stock Titan
PXMD Stock Price, News & Analysis - Stock Titan
CNBX Pharms Stock Price, News & Analysis - Stock Titan
PaxMedica announces board resignations amid transition - Investing.com
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Groundbreaking China Patent for Autism Treatment Breakthrough After 100 Years - Stock Titan
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - Yahoo Finance
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
Tardimed Sciences Llc Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - GlobeNewswire
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA - marketscreener.com
PaxMedica Receives Emergency Request for IV Suramin from - GlobeNewswire
Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies By Benzinga - Investing.com UK
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission - Yahoo Finance
PaxMedica, Inc. (PXMD) stock price, news, quote and history - Yahoo Finance UK
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
HC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy Recommendation - Nasdaq
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
PaxMedica prices stock and warrant offering at $1.30 per unit By Investing.com - Investing.com Canada
PaxMedica progresses with PAX-101 for sleeping sickness By Investing.com - Investing.com UK
PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast - GlobeNewswire
PaxMedica Surges After Publication Of Statistically Significant Data From Its Autism Spectrum Study - Nasdaq
Gapping stocks in Tuesday's session - ChartMill
PaxMedica Announces 1-for-17 Reverse Stock Split - Yahoo Finance
PaxMedica (NASDAQ: PXMD) Reports on Low-Dose Suramin for ASD Research - Digital Journal
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication - GlobeNewswire
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD) - GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Which stocks are moving before the opening bell on Monday? - ChartMill
PaxMedica Comments on Common Stock Volatility - GlobeNewswire
PaxMedica CEO Interviewed by The BRAIN Foundation - GlobeNewswire
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - Clinical Trials Arena
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder - GlobeNewswire
PaxMedica and PoloMar to investigate emodin in ASD trial - Clinical Trials Arena
PaxMedica Enters Research Collaboration Agreement With - GlobeNewswire
PaxMedica Completes HAT-301 Registrational Trial for PAX-101 - GlobeNewswire
PaxMedica, Inc. Provides First Quarter 2023 Business - GlobeNewswire
PaxMedica Holds Meeting of Scientific Advisory Board - GlobeNewswire
These stocks are moving in today's pre-market session - ChartMill
팩스메디카 (PXMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
0.07%
자본화:
|
볼륨(24시간):